While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
A business making money today isn’t necessarily a winner, which is why we analyze companies across multiple dimensions at StockStory. That said, here is one profitable company that generates reliable profits without sacrificing growth and two that may face some trouble.
Two Stocks to Sell:
Fastenal (FAST)
Trailing 12-Month GAAP Operating Margin: 20.2%
Founded in 1967, Fastenal (NASDAQ: FAST) provides industrial and construction supplies, including fasteners, tools, safety products, and many other product categories to businesses globally.
Why Do We Think Twice About FAST?
- Muted 5.7% annual revenue growth over the last two years shows its demand lagged behind its industrials peers
- Earnings growth underperformed the sector average over the last two years as its EPS grew by just 4.4% annually
Fastenal is trading at $46.03 per share, or 38x forward P/E. Dive into our free research report to see why there are better opportunities than FAST.
Bio-Techne (TECH)
Trailing 12-Month GAAP Operating Margin: 9.6%
With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ: TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development.
Why Do We Avoid TECH?
- Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
- Subscale operations are evident in its revenue base of $1.22 billion, meaning it has fewer distribution channels than its larger rivals
- Free cash flow margin shrank by 11.6 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
At $60.07 per share, Bio-Techne trades at 29x forward P/E. Read our free research report to see why you should think twice about including TECH in your portfolio.
One Stock to Watch:
Elevance Health (ELV)
Trailing 12-Month GAAP Operating Margin: 4.1%
Formerly known as Anthem until its 2022 rebranding, Elevance Health (NYSE: ELV) is one of America's largest health insurers, serving approximately 47 million medical members through its network-based managed care plans.
Why Are We Positive On ELV?
- 10.3% annual revenue growth over the last five years was better than the sector average, highlighting the value of its products and services
- Enormous revenue base of $197.6 billion gives it leverage over plan holders and advantageous reimbursement terms with healthcare providers
- Industry-leading 27.2% return on capital demonstrates management’s skill in finding high-return investments
Elevance Health’s stock price of $340 implies a valuation ratio of 13.3x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it’s free.
High-Quality Stocks for All Market Conditions
Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.
The names generating the next wave of massive growth are right here in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
